## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 19 May 2005 (19.05.2005)

**PCT** 

## (10) International Publication Number WO 2005/044259 A1

(51) International Patent Classification7:

A61K 31/40

(21) International Application Number:

PCT/US2004/013252

(22) International Filing Date: 28 April 2004 (28.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10/699,154

30 October 2003 (30.10.2003) US

(71) Applicant (for all designated States except US): CEL-GENE CORPORATION [US/US]; 7 Powder Horn Drive, Warren, NJ 07059 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZELDIS, Jerome, B. [US/US]; 157 Christopher Drive, Princeton, NJ 08540 (US).

(74) Agents: INSOGNA, Anthony, M. et al.; Jones Day, 222
East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITION AND METHOD FOR TREATING MACULAR DEGENERATION

(57) Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.